Biogen, Inc. BIIB will report first-quarter 2024 results on Apr 24, before market open. In the last reported quarter, the ...

Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), ...

Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ...

Sage Therapeutics said on Wednesday it would stop working on its experimental drug for Parkinson's disease after the ...

After getting a fat check worth $30.5 million for joining Biogen as the CEO in late 2022, Chris Viehbacher saw his 2023 pay drop to $4.1 million as the Big Biotech continues to struggle. | After ...

Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform' ...

Biogen Inc. ( NASDAQ:BIIB) is an American biopharmaceutical company specializing in the development and commercialization of ...

Medicare estimates that a new Alzheimer’s treatment could cost the program billions of dollars by next year — well beyond ...

The series, Rethinking Alzheimer’s Disease, will focus on steps listeners can take to lower their risk of developing the ...

In terms of liquidity and interest, the mean open interest for Biogen options trades today is 95.5 with a total volume of 647 ...